ICU Medical (ICUI) to Release Earnings on Tuesday

ICU Medical (NASDAQ:ICUI) is set to post its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect ICU Medical to post earnings of $1.25 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The firm had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter last year, the business earned $1.58 earnings per share. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Trading Down 1.0 %

Shares of ICUI stock opened at $176.79 on Friday. The stock has a market cap of $4.32 billion, a P/E ratio of -60.54 and a beta of 0.66. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The business has a fifty day simple moving average of $175.30 and a 200-day simple moving average of $140.27.

Analysts Set New Price Targets

A number of brokerages have issued reports on ICUI. KeyCorp lifted their target price on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Jefferies Financial Group started coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 target price for the company. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $170.25.

Insider Buying and Selling at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,973,261.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now owns 13,107 shares in the company, valued at approximately $2,139,324.54. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $17,973,261.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,502 shares of company stock worth $8,445,976 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.